Skip Navigation
Office of Management
Office of Financial Management
Print this page
Back to Budget Documentation Page
Back to FY 2006 Budget Summary
Table of Contents
Animal Drugs and Feeds
Center For Veterinary Medicine (CVM)
|
FY 2004 Actual
|
FY 2005 Enacted 1/
|
FY 2006 Estimate
|
Increase or Decrease
|
Program Level
|
$67,656,000
|
$75,658,000
|
$78,338,000
|
+$2,680,000
|
Total FTE |
349 |
373 |
385 |
+12 |
Budget Authority
|
$66,573,000
|
$67,551,000
|
$67,769,000
|
+$218,000
|
GSA Rent & Rent Related |
$12,043,000 |
$12,259,000 |
$12,477,000 |
+$218,000 |
Total FTE |
346 |
315 |
309 |
-6 |
User Fee
|
$1,083,000
|
$8,107,000
|
$10,569,000
|
+$2,462,000
|
ADUFA |
$1,083,000 |
$8,107,000 |
$10,569,000 |
+$2,462,000 |
FTE |
3 |
58 |
76 |
+18 |
ORA Estimate |
Budget Authority
|
$33,080,000
|
$39,383,000
|
$39,519,000
|
+$136
|
FTE |
246 |
240 |
228 |
-12 |
Includes structure changes to FDA's budget, which displays GSA and
Other Rent and Rent Related Activities in the Program line, and the Office
of Regulatory Affairs as its own program. ORA estimates are for information
purposes only and are not included in the Center program level total.
1Contains budget authority rescission of 0.8 percent.
Historical Funding and FTE Levels |
Fiscal Year
|
Program Level
|
Budget Authority
|
User Fees
|
Program Level FTE
|
2002 Actual 1/
|
$55,727,000
|
$55,727,000
|
$0
|
323
|
2003 Actual
|
$57,115,000
|
$57,115,000
|
$0
|
341
|
2004 Actual
|
$67,656,000
|
$66,573,000
|
$1,083,000
|
349
|
2005 Enacted
|
$75,658,000
|
$67,551,000
|
$8,107,000
|
373
|
2006 Estimate
|
$78,338,000
|
$67,769,000
|
$10,569,000
|
385
|
Does not contain GSA Rent or Other Rent and Rent Related Activities.
1/Includes FDA's FY 2002 Appropriation and the Counterterrorism Supplemental.
Statement of Budget Request
The Animal Drugs and Feeds Program is requesting $78,338,000 in program
level resources to accomplish its mission activities including:
- Foster public and animal health by approving safe and effective
products for animals and by enforcing applicable provisions of the Federal
Food, Drug, and Cosmetic Act, and other authorities;
- Process premarket applications as quickly as possible to increase
the availability and diversity of safe and effective veterinary products
that relieve animal pain and suffering while ensuring the resulting products
are safe, wholesome, and free of drug residue when they reach the consumer;
and,
- Monitor marketed products for all animal drugs and feeds to
minimize harm to humans or animals that might arise from the use of these
products. This is accomplished through science-based review of drug experience
reports, nationwide monitoring systems, compliance programs conducted
by FDA field offices through inspections, sample collections, analysis,
investigations,
and appropriate regulatory actions to control violative goods and firms.
Program Description
The Animal Drugs and Feeds Program (Program) is administered by FDA's
Center for Veterinary Medicine (CVM) and supported by the Office of Regulatory
Affairs' (ORA) field force. The authority to regulate animal drugs and
medicated feeds is derived from the Food, Drug, and Cosmetic Act, which
in 1968 was amended to include sections specifically addressing animal
drugs. These amendments were designed to ensure that animal drugs are safe
and effective for their intended uses and that the drugs do not result
in unsafe residues in foods. In November 2003, the Animal Drug User Fee
Act was enacted that provided the authority for FDA to collect user fees
for its animal drug review work. The new law is intended to supplement
the appropriated resources for conducting the animal drug review program.
These resources provided by the law will help the Animal Drugs and Feeds
Program's scientists keep pace with the rapid advances in science and medicine
that drive the quality of health care for animals.
The Animal Drugs and Feeds' Program scope is far-reaching. The
program's customers include:
- 115 million dogs and cats
- 6.9 million horses
- 7.5 billion chickens
- 292 million turkeys
- 109 million cattle
- 92 million pigs
- 7 million sheep
- 293 million humans in the U.S.
|
The safety of the food supply is a paramount concern for the Program,
as the average American consumes nearly 200 pounds of meat and fish, 30
pounds of eggs, and 600 pounds of dairy products each year. While most
of these food products are regulated by the USDA FDA plays a key role in
ensuring that animal drugs and feeds used in the care of these animals
do not result in unsafe residues in food products that are harvested or
produced (e.g., eggs) from these animals.
ORA supports the CVM, by conducting preapproval inspections of both domestic
and foreign establishments and other premarket-related activities such
as: bioresearch monitoring of clinical research and laboratory method validations
needed for premarket application decisions, and inspections of manufacturing
facilities to determine if the factory is able to manufacture the product
to the specifications stated in the application. In addition to overseeing
regulated products on a surveillance or "for cause" basis, ORA staff also
responds to emergencies and investigates incidents of product tampering
and terrorist events or natural disasters. To complement the regular field
force, the Office of Criminal Investigations investigates instances of
criminal activity in FDA regulated industries. In FY 2006, ORA will expend
an estimated $39,519,000 in support of the Animal Drugs and Feed Program.
The Program's other priorities are animal drug review, antibiotic resistance,
prevention of Bovine Spongiform Encephalopathy (BSE) or "mad cow disease," and
the safety of food derived from genetically modified animals. Of these
priorities, efforts have sought to limit the exposure of BSE in the food
and feed supply began in 1997 when FDA issued a regulation prohibiting
the use of most animal proteins in feeds for cattle and other ruminants.
In its enforcement strategy, FDA initiated a comprehensive inspectional
program using the Field and its state partners covering 100 percent of
the affected industry. With its educational emphasis and other outreach
efforts, the result has been that more than 99 percent of all renderers
and feed mills in the U.S. who process prohibited material now comply with
this regulation. Concurrent with this approach was the development of a
response planning mechanism coordinated by FDA's Office of Crisis Management
that would be used when a BSE-positive animal was discovered. In addition,
FDA began to monitor imports through entry review of all feed and feed
ingredient commodities and sampling for the presence of processed animal
protein. In late December 2003, a BSE-positive animal was identified and
the response plan went into action. A series of inspections and trace-back
procedures were instituted which determined that all of the BSE-infected
materials were recovered. In mid-January 2004, FDA announced additional
safeguards to protect the public from becoming exposed to infected BSE
material in the food supply.
Performance Analysis
During the latest completed performance period, (FY 2004), CVM achieved
the targets for two of its three performance goals, and expects to meet
the other one when data becomes available in
October 2005. For more detailed explanation of these goals and results,
please see their respective section contained in the Detail of Performance
Analysis under the Supporting Information tab.
With the passage of the Animal Drug User Fee Act (ADUFA) of 2003 and
the resulting availability of user fees, the Program changed its new animal
drug review performance goals to reflect the more ambitious performance
target plans under ADUFA. Since the ADUFA fee structure is predicated on
supplementing existing appropriated funding, the request must be designed
to ensure that budgetary authority and user fees are adequate. The performance
goal and target below is dependent upon a sustained level of base and user
fee resources.
Performance Highlight: |
Goal Target
|
Context
|
Results
|
Complete review and action on 90% of original NADAs & reactivations
of such applications received in FY 2006 within 230 days.
|
The user fee program reflects the implementation of a five (5) year
plan to improve the performance for animal drug review.
|
The benefits provided by the user fee program include: shorter review
times; a more predictable and stable review process; and overall
reduction in drug development times.
|
Rationale for Budget Request
This request for Budget Authority and User Fees supports various activities
that contribute to the accomplishment of program outputs and performance
goals, and presents FDA's justification of base resources and selected
FY 2004 accomplishments by strategic goal.
Program Resource Changes
Program Account Restructuring
GSA Rent and Other Rent Activities Structure Change
To provide increased flexibility and accountability, eliminate the need
for the many reprogramming requests to Congress, place accountability for
rental costs within the operating program, would better reflect the total
cost of each program. This budget changes the way the GSA Rent and Other
Rent-Related Activities budget lines are displayed by incorporating these
resources into the Animal Drugs and Feed program level requests.
Office of Regulatory Affairs (ORA) Estimate and Structure Change
This budget also establishes a single budget line item for the ORA. To
help the field program provide services more effectively, especially by
providing much needed flexibility to respond to shifting program priorities.
This additional flexibility is essential to allow FDA to respond to emerging
situations without being hindered in performing its mission critical activities.
These activities have been removed from each program line and the Field
estimates will be provided under the Office of Regulatory Affairs to reflect
the
planned spending for each program area.
Budget Authority
GSA Rent + $218,000
To help meet the rising costs of GSA rent, a total increase of $4,100,000
is requested, of which $218,000 is for the Center for Veterinary Medicine.
This increase will help cover inflation on FDA's current GSA leased facilities.
User Fee
Animal Drug User Fee Act (ADUFA): + $2,462,000 and + 18 FTE
ADUFA enacted in November 2003, contained a required appropriations action enabling
FDA's implementation of ADUFA. ADUFA helps the FDA, through a strengthened animal
drug pre-market review program, to provide greater public health protection by
ensuring that animal drug products that are approved to be safe and effective
are readily available for both companion animals and animals intended for food
consumption. Additional resources provided by ADUFA will also help FDA scientists
keep pace with the rapid advances in science and medicine that drive the quality
of health care for our animals. ADUFA, which requires new animal drug applicants,
sponsors, and establishments to incur a fee to expedite their respective applications,
will help provide a cost-efficient, high quality animal drug review process that
is predictable and performance driven. This increase of $2,462,000 will cover
inflationary costs, as well as overhead and rent costs, for additional staff
associated with the Act.
Justification of Base
Using Risk-based Management Practices
Base resources will be used to conduct science-based risk management
in all agency regulatory activities; so that the agency's limited resources
can provide the most health promotion and protection at the least cost
for the public. These activities include premarket review compliance activities
related to the BSE regulation and imports and inspections.
Bovine Spongiform Encephalopathy (BSE)
BSE or "Mad Cow Disease" is a deadly chronic, degenerative disorder
affecting the central nervous system. Feed containing remnants of the slaughtering
process, such as the brain and spinal cord, may harbor the agent that causes
BSE. To ensure such substances are not contained in animal feed, and to
prevent the establishment and amplification of BSE through animal feed,
the FDA finalized a regulation on August 4, 1997 entitled "Animal Proteins
Prohibited from use in Animal Feed". FDA will:
- Conduct annual, targeted BSE inspections of all known renderers
and feed mills processing products containing prohibited material, such
as meat and bone meal;
- Conduct selected inspections of animal feed industry firms subject
to the animal protein prohibition, including renderers, feed mills, feed
distributors, feed retailers, transporters, on-farm mixers, and ruminant
feeders;
- Issue and coordinate assignment for directing identification
and inspections of firms engaged in animal feed salvaging and feed transportation;
- Implement enforcement actions and conduct re-inspections involving
firms found
to be in violation of the regulation;
- Issue and implement import alerts and bulletins regarding animal
feed, animal feed ingredients and other products for animal use consisting
of or containing ingredients of animal origin from both countries at-risk
and not at-risk for BSE;
- Collect and analyze samples of domestic and imported feeds and
feed ingredients to monitor for the presence of prohibited animal proteins;
- Maintain relationships with industry using telecommunication
and conferences to provide information on regulatory compliance and share
inspection data;
- Develop and validate an improved method for detecting prohibited
animal proteins in feed using Real Time PCR (Polymerase Chain Reaction)
that will allow for the identification of up to four different prohibited
species in a single reaction;
- Adapt the Real Time PCR methodology to identify prohibited animal
proteins in rendered materials from the European Union as well as materials
rendered in the United States;
- Continue to evaluate commercially available rapid tests for
prohibited proteins in animal feeds;
- Maintain the database and data entry procedures for BSE inspections,
and new BSE inspection checklist to target firms for re-inspections and
to collect high quality data from both FDA and state inspectors;
- Maintain a web-based, dynamic report available to the public
and other health related agencies that summarizes the most current information
concerning the results of inspections involving all firms subject to
BSE inspections;
- Test proposed risk management proposals in terms of the effects
on the spread and the rate of elimination of BSE, if introduced into
the U.S., with the help of the Harvard BSE Risk Assessment simulation;
- Leverage with state agencies by funding contract inspections
of feed mills and renderers, and conduct compliance, follow-up, and audit
inspections to state contracts;
- Provide education to state feed control officials and FDA investigators
on policies and inspectional procedures concerning the animal protein
prohibition through training seminars, courses and feed safety meetings;
and,
- Provide intensive line entry and label review of Animal Drug
and Feed product import line entries for use in domestic commerce.
Premarket Review
The availability of safe and effective animal drugs allows food animal
producers to maintain healthy animals with assurance that products will
be safe, wholesome, and free of harmful drug residues when they reach the
consumer. FDA strives to improve product review performance and meet the
increasing complexity of review workload. Keeping pace with technological
advances will contribute to the efficiency of agency reviews, and decrease
review time. FDA will:
- Continue to increase the availability of safe and effective
animal products, by reviewing animal drug applications in a timely manner
for safety and effectiveness, and continue to work with regulated industry
to minimize drug development time;
- Conduct pre-submission conferences, meetings, and workshops
with industry and develop policy and practical guidance documents as
necessary to industry;
- Continue implementation of the ADUFA;
- Continue the enhanced review performance achieved in FY 2004;
- Improve the quality and timeliness of product reviews by monitoring
pre-approval inspections and expanding inspectional expertise in emerging
technologies;
- Review previously approved new animal antimicrobial drug submissions
with respect to antimicrobial resistance and human food safety;
- Conduct method validation studies for the approval of applications
for new drugs for food producing animals;
- Continue development and validation of multi-residue drug screening
methods;
- Resolve new and emerging scientific issues that impact on the
CVM's ability to make approval decisions; and,
- Prepare implementation regulations for the Minor Use and Minor
Species Animal Health Act of 2004 (MUMSAHA) to help make more medications
legally available to veterinarians and animal owners to treat minor animal
species and also uncommon diseases in the major animal species.
Empowering Consumers for Better Health
Base resources will be used to better enable consumers to make informed
decisions weighing benefits and risks of FDA-regulated products. These
activities include:
- Delivering food safety and veterinary health messages to livestock
producers, veterinarians, industry and consumers via trade shows, videotapes,
and pamphlets to educate them on safe drug use, including prudent use
of antibiotics in food animals to minimize the risk of antimicrobial
resistance;
and,
- Enhancing the transparency of the National Antimicrobial Resistance
Monitoring System (NARMS) program to stakeholders, the public and other
interested parties by increased reporting and communications of NARMS
results and program information by: publishing annual reports of animal,
human
and retail meat data; posting NARMS publication references on the web,
and presenting NARMS susceptibility testing results at scientific meetings
via poster or oral presentations.
Patient and Consumer Protection
Base resources will be used to promote improved patient and consumer
safety by reducing risks associated with FDA-regulated products.
Food Safety
Millions of people get sick annually from food they eat. Some foodborne
illnesses are due to harmful or illegal residues in animal products while
other illness is due to microbiological infection. In order to safely manage
animal drug use at home and abroad, we must have the knowledge to make
proactive, sound science based decisions. In pursuit of these objections
the Agency will:
- Continue the retail meat arm of NARMS by monitoring changes
in antimicrobial drug susceptibilities of selected enteric bacterial
organisms in retail meats to a panel of antimicrobial drugs important
in human and
animal medicine;
- Continue research to identify food animal species causing human
drug resistance;
- Provide educational information on biotechnology products and
assist developers through the regulatory process;
- Continue to support the World Health Organization's Global Salmonella
Surveillance;
- Continue leveraging FDA's Tissue Residue Information Management
System (RVIS) with the USDA's Residue Violation Information System to
Maintain Tissue Residue and Feed contaminants compliance programs;
- Continue FDA field inspections and take appropriate regulatory
and enforcement action against firms illegally compounding animal drugs;
- Develop intervention measures to establish additional controls
over the shipment, receipt, and use of bulk active pharmaceutical ingredients
in compounding animal drugs; and,
- Maintain early warning systems by collecting information from
Drug Experience Reports and Adverse Event Reports.
Protecting the Homeland -- Counterterrorism
The goals of the Program are to protect the health and safety of all
food producing, companion, and other non-food animals; and assure that
food from animals is safe for human consumption. FDA must work to develop
profiles of possible or probable food threats and points of attack and
must have the capacity to quickly and accurately identify outbreaks at
any point in the food chain, and take prompt action to mitigate their effects.
Base funding will enable FDA to:
- Sample domestic animal feeds and those detained at U.S. ports
of entry that contain ingredients possibly derived from prohibited animal
material;
- Strengthen relationships with state partners and solicit interest
in the expansion of contracting efforts with state laboratories to provide
surveillance and surge capacity related to counter terrorism activities;
- Work with Iowa State University on a database that assists "first
responders" by providing quick identification of qualified labs that have
the capability to analyze feed and/or animal tissues for the presence of
a chemical or biological agent, immediate contact with national experts
on the disease or toxicant to obtain help in diagnosis and appropriate
follow-up, and information on how to take, preserve, and ship an appropriate
feed or animal sample to the laboratory for analysis;
- Continue developing more efficient rapid analytical methods
for screening imports at the border;
- Develop a list of high priority products for countermeasures
and periodically review and update list;
- Assist state diagnostic laboratories in acquiring the scientific
expertise, analytical expertise and capability to handle a feed contamination
incident;
- Maintain a comprehensive inventory of registered animal drug
establishments and listed animal drug products and use the database to
assess the availability or anticipated shortage of animal drug products
that would be needed to deal with terrorist attacks;
- Continue to develop analytical methods to detect the presence
of prohibited toxic substances that could be introduced into U.S. animal
feed supplies. Once developed and optimized, these methods would be used
by FDA laboratories to test prohibited substances in routine animal feed
surveys;
- Work with CDC on a bioterrorism surveillance system for companion
animals that can be used as an early detection mechanism; and,
- Intensify the review of products offered for import and collaborate
with the Custom Service on safety and security issues at ports of entry.
Selected FY 2004 Accomplishments
Using Risk-based Management Practices
Bovine Spongiform Encephalopathy (BSE)
- For fiscal year 2004, inspected over 6,806 renderers, feed mills,
and other firms, including on-farm mixers and ruminant feeders, to determine
compliance with the BSE feed regulations. At the end of the FY 2004,
17 firms were classified as being out of compliance at the time of their
last
inspection. Re-inspections of these facilities determined to be out of
compliance with the BSE regulation are still on-going;
- FDA and state investigators specifically inspected a high-interest
subset of 645 firms as part of our annual BSE performance goal feed inspections
obligation. This subset represented 100 percent of all known renderers
and feed mills processing products containing prohibited material;
- In July 2004, co-published with USDA an advanced notice of proposed
rulemaking (ANPRM) requesting comments and scientific information on
several additional regulatory measures that would strengthen the feed
regulation;
- Developed a real-time Polymerase Chain Reaction (PCR) based
method capable of detecting cattle, swine, sheep, goats, horses, or deer
material along with poultry, goose, and turkey for use in analyzing samples
of animal feeds and feed ingredients in support of the animal protein
prohibition;
- Evaluated two commercially available diagnostic test marketed
to detect mammalian proteins in animal feed and feed ingredients;
- Issued
10 Warning Letters for animal proteins prohibited in ruminant feed,
and 15 class II recalls involving 15 firms and 25 products
in response to violations of the BSE rule;
- Issued assignments for collection of 600 samples from domestic
animal feeds, 300 samples of animal feeds imported from countries not
considered at risk for BSE, and 300 samples of animal feeds imported
from countries
considered at risk for BSE for subsequent feed analysis to determine
possible non-compliance with the ruminant feed ban regulation and the
import alert
prohibiting importation of feeds containing animal tissues;
- Provided separate formal ruminant feed ban inspection training
seminars to feed safety officials in the states of Montana, Washington,
Oregon, New York, Wisconsin, Oklahoma, and Idaho;
- Participated in BSE working groups at three separate meetings
of the Association of American Feed Control Officials;
- Provided staffing to the FDA and USDA/APHIS emergency operation
centers, tracking the distribution and disposition of suspect material,
communicating with state authorities, and overseeing the final disposition
of destruction of suspect material after discovery of a BSE-infected
cow in the U.S.; and,
- Issued Guidance for Industry (GFI #174) for the disposition
of material from BSE positive cattle in animal feed.
Premarket Review
- Approved the following noteworthy medicines.
- SIMPLICEF (cefpodoxime proxetil) new chemical entity to treat
skin infections (wounds and abscesses) in dogs caused by susceptible
strains of Staphylococcus intermedius, Staphylococcus aureus, Streptococcus
canis (group G, β hemolytic), Escherichia coli, Pasteurella
multocida, and Proteus mirabilis.
- EXCEDE for Swine (ceftiofur crystalline free acid) sterile suspension -EXCEDE
for Swine is an antimicrobial indicated for the treatment of swine respiratory
disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella
multocida, Haemophilus parasuis, and Streptococcus suis.
- METACAM Injectable Solution (meloxicam) original approval
for the control of pain and inflammation associated with osteoarthritis
in dogs.
- NAVIGATOR Oral Paste (nitazoxanide) new chemical entity
for the treatment of equine protozoal myeloencephalitis (EPM).
- ULCERGARD (omeprazole) Oral Paste original OTC approval
for the prevention of gastric ulcers in horses.
- VETSULIN (insulin) new chemical entity and the first veterinary
insulin approval. The product is approved to treat hyperglycemia
and hyperglycemia-associated with diabetes mellitus in dogs.
- BUSCOPAN Injectable Solution (N butylscopolammonium bromide)
new chemical entity for the control of pain associated with spasmodic
colic, flatulent colic and simple impactions in horses.
- SURPASS Topical Anti-inflammatory Cream (diclofenac) new
chemical entity for the control of pain and inflammation associated
with osteoarthritis
in horses.
- SEDIVET Injectable Solution (romifidine hydrochloride) new
chemical entity for use as a sedative and analgesic for the facilitation
of handling, examination, and minor surgical manipulations in horses.
- PREVICOX Tablets (firocoxib) new chemical entity for the
control of pain and inflammation associated with osteoarthritis in
dogs.
CVM Approves First 4-Way Combination Drug
CVM recently approved the first four-way drug combination product
under the Animal Drug Availability Act of 1996 (ADAA) that eased
the requirements for combination approvals.
Before ADA, a drug sponsor had to prove the effectiveness of each
drug in the combination drug. Under ADAA, the sponsor faces no
additional
requirements to prove effectiveness of combinations made up of previously
approved drugs. The sponsor needs only to show that each drug brings
an additional claim to the combination and the drug's safety is not
diminished. For combination drugs, ADAA "streamlined the process" and
removed certain regulatory hurdles.
The recently approved four-way combination product is
an over-the-counter Type A medicated feed article approved for
use in heifers fed in
confinement for slaughter. The product is made up of four previously
approved products-Optaflexx (ractopamine hydro-chloride), Rumensin
(monensin sodium), Tylan (tylosin phosphate) and MGA (melengestrol
acetate). The sponsor is Elanco Animal Health.
This combination product is approved for increased rate of weight
gain, improved feed efficiency, increased carcass leanness, the
prevention
and control of coccidiosis due to Eimeria bovis and E. zuernii, reduction
of incidence of liver abscesses caused by Fusobacterium necrophorum
and Actinomyces (Corynebacterium) pyogenes and suppression of estrus. |
- Issued a regulation describing the procedures for requesting,
conducting and documenting presubmission conferences;
- Issued draft Guidance for Industry (GFI #169) on the chemistry,
manufacturing and controls information to be submitted for certain drug
substances to ensure continued drug substance and drug product quality;
- Issued draft Guidance for Industry (GFI #162) for preparing
and using comparability protocols for changes in chemistry, manufacturing
and controls of protein drug products;
- Issued draft Guidance for Industry (GFI #135) for validation
of analytical procedures for Type C medicated feeds;
- Issued draft
Guidance for Industry (GFI #171) for waiver of in vivo demonstration
of bioequivalence of animal drugs in soluble powder
oral dosage form products and Type A medicated articles;
- Issued draft and final guidance documents resulting from collaborative
efforts with industry and international regulatory partners within VICH
to harmonize preapproval guidance;
- Completed a Public Master File for tylosin through the National
Research Support Project #7 (NRSP-7) initiative for the control of American
Foulbrood Disease in honeybees. An announcement of the availability of
these data was published in the Federal Register. These data may now
be used by reference to support a New Animal Drug Application for this
claim;
and,
- Held a NSRP-7 meeting with stakeholders in the spring to improve
the communication between producer groups, the regulated industry, and
government.
Minor Use and Minor Species Animal Health Act of 2004 (MUMSAHA)
- On August 2, 2004, President signed The Minor Use and Minor
Species Animal Health Act of 2004 (MUMSAHA) to help make more medications
legally available to veterinarians and animal owners to treat minor animal
species and also uncommon diseases in the major animal species; and,
- Established the new Office of Minor Use and Minor Species Animal
Drug Development, as mandated by MUMSAHA.
New "MUMS" Legislation to Help Make Animal Drugs Available for
Limited Uses, Minor Species
President Bush has signed legislation that will help make
more medications legally available to veterinarians and animal
owners to treat minor animal species and uncommon diseases in the
major animal species.
The goal of this legislation is to provide incentives to pharmaceutical
companies to develop drugs for limited uses and to provide some
alternative approaches to the usual drug approval process for limited-use
animal drugs, thus changing the economic outlook for the drug approval
process.
In addition, the measure is expected to benefit people who
own small or unusual pets such as guinea pigs or ornamental fish,
and will likely aid zoo veterinarians. Before this, pharmaceutical
companies could rarely afford to bring to market drugs for novel
pets and zoo animals. The markets were just too small to generate
an adequate financial return.
Minor use drugs are drugs for use in major species (cattle,
horses, swine, chickens, turkeys, dogs and cats) that are needed
for diseases that have a limited geographic range or affect a small
number of animals. Minor species includes all animals other than
the major species, which includes zoo animals, ornamental fish,
parrots, ferrets and guinea pigs. Some animals of agricultural
importance are also minor species. These include sheep, goats,
catfish and honeybees.
|
Animal Drug User Fee Act (ADUFA)
- Implemented ADUFA by hiring reviewers, developing procedures
for applying the new law, and establishing fee rates and payment procedures;
- FDA met or exceeded all review times defined under ADUFA for
FY 2004 for applications and submissions that have been acted on as of
September 30, 2004. Additional applications and submissions received
in FY 2004 are pending review and action, but are still within ADUFA
time
frames;
- The 833 submissions not associated with abbreviated new animal
drug applications (ANADAs) that were pending before September 30, 2003,
have been reviewed and acted upon. FDA was required to review
and act on pending NADAs, supplemental NADAs, and INAD submissions within
24
months after user fee payments were initiated;
- FDA has made substantial progress in recruiting for its review
staff and will meet its goal of having 50 percent of additional FDA review
staff recruited and on-board by the first quarter of FY 2006;
- On March 15, 2004, FDA published Guidance for Industry (GFI
#170) "Animal Drug User Fees and Fee Waivers and Reductions" to help industry
understand the ADUFA fee structure and the options available to individuals
who qualify for a fee waiver or reduction;
- On September 28, 2004, FDA published draft Guidance for Industry
(GFI #173) "Animal Drug Sponsor Fees under the Animal Drug User Fee Act";
- The implementation included developing and publishing in the
Federal Register the fees for FY 2004 and 2005, as follows: Establishment
of Animal Drug User Fee Rates for Applications for FY 2004 and Payment
Procedures on February 18, 2004; Establishment of Animal Drug User
Fee Rates and Payment Procedures for Product, Establishment, and Sponsor
Fees for FY 2004 on April 27, 2004; and, Establishment of Animal
Drug User Fee Rates and Payment Procedures for FY 2005 On August
2, 2004; and,
- The financial implementation also included an electronic prototype
for FDA that fully automated the application fee collection and billing
process using a web based front-end tool called the IStore. The
ADUFA implementation highlights FDA progress in improving financial management,
budget and performance integration, and in expanding E-government in
strategic alignment with the President's Management Agenda.
Biotechnology
- The Animal Biotechnology Working Group made progress concentrating
its effort on ensuring personnel are aware of the critical issues in
biotechnology, possess the scientific skills necessary to address the
rapidly evolving
and highly technical issues associated with animal biotechnology, and
are familiar with the regulatory environment surrounding those issues;
- As part of staff development program, instituted a rotating
detail program for reviewers with senior staff to acquaint them with
policy development and potential implementation in animal biotechnology;
- Continued to develop a transgenic animal policy. Participated
in White House-level deliberations to evaluate the role of genetically
engineered animals in the Coordinated Framework for the Regulation of
Biotechnology. Prepared case studies on animal biotechnology products
to serve as a basis
for legal and policy deliberations. Participated in listening sessions
sponsored by the Office of Science and Technology Policy with stakeholders
from industry, the research community, and non-government organizations;
- Continuing to work with sponsors of animal biotechnology products
to ensure that their progress is responsible but not duly burdened as
the Federal government prepares a policy on transgenic animals; and,
- Completed draft Risk Assessment on Animal Clones and their Progeny;
prepared a Proposed Risk Management Plan and a draft Guidance for Industry
on the use of cloning technology in animal breeding and release of clones
and their progeny into the food supply; briefed the Secretary's staff
on the cloning package.
Aquaculture
- Determined the effectiveness of formalin treatments to reduce
mortality associated with fungal infections in rainbow trout. The data
was submitted to a public master file for use in possible approvals for
drugs for fish under the Minor Use Minor Species program;
- Continued to standardize methods for antimicrobial susceptibility
testing (AST) of microorganisms in aquatic species by developing a broth
micro dilution AST method. Standardized methods are necessary for monitoring
antimicrobial resistance in aquaculture;
- Developed a relational database of information on pharmacokinetic
parameters in fish that provides a rapid access to data about the metabolism,
accumulation, and elimination of drugs or chemicals in fish tissues;
- Conducted a number of studies to provide incurred residues of
drugs in fish tissues to support the development of methods for detecting
drug residues in fish tissues. One such study provided incurred tissues
for development of a single method for detecting multiple drug residues
in fish;
- Coordinated and collaborated in a study to compare a chemical
method and a microbiological method for detecting erythromycin in fish
tissues;
- Developed an internal parasite infection model in largemouth
bass. These fish containing the internal parasite will be used to test
the effectiveness of various drugs for the treatment of the infection;
and,
- Developed a Risk Assessment Tool to evaluate data collected
on the risk of drugs used in foreign aquaculture that will help assess
possible hazardous drug residues in food and prioritize them for analytical
method development and drug residue monitoring.
Imports, Inspections, and Surveillance
- Issued a guidance describing the four conditions veal producers
needed to meet to be able to sell their calves for veal that were illegally
implanted with hormone implants;
- Issued a Guidance For Industry (GFI #122) "Manufacture and Labeling
of Raw Meat Foods for Companion and Captive Non-companion Carnivores and
Omnivores" which contains specific recommendations manufacturers can take
to decrease the health risks to the public from handling and feeding raw
meat diets to their animals;
- Issued a notice in July 2004 reminding
dairy producers and others that they should not feed milk replacer products
that contain neomycin
to calves that could go to slaughter as veal;
- Investigated 743 tissue residue violations via our compliance
program resulting inissuing105 tissue residue-related Warning Letters,
and 3 injunctions against dairy farms that had marketed cows and calves
whose edible tissues contained illegal drug residues;
- Initiated use of a drug inventory survey form by investigators
who make on-farm visits to help establish priorities for drugs to be
included in the USDA National Residue Plan;
- Met with various trade associations and issued an assignment
to FDA District Offices to inspect 20 compounding pharmacies to reduce
the risk from use of compounded veterinary drug products in food-producing
and non-food-producing animals;
- Completed inspections of more than half of the approximately
1141 FDA-licensed medicated feed mills in the United States;
- Completed 50 feed recall events. Thirty-tree of the 50 recall
events were feed related. Fifteen of the 33 recalls were related to BSE
feed regulation;
- Assisted the states in reviewing feed labeling and pursued regulatory
action if necessary. Completed 131 label reviews;
- Per FDA's request, the manufacturer of the heartworm medication
ProHeart6 agreed in September 2004 to cease production immediately and
recall the drug from the market until FDA's concern about adverse reaction
reports associated with the product could be resolved;
- Reviewed and summarized comments received from a two-day public
meeting in September 2003, with industry, government and public consumers,
to discuss the potential development of a comprehensive, risk-based Animal
Feed Safety System. Prepared a report identifying the strengths and weaknesses
of current U.S. and international programs. Made available the draft
definitions for comprehensive and risk-based, and the basic elements
of process control
for public review. All were placed in the AFSS docket to allow for public
comment;
- Issued FACTS Assignment #539994 entitled "Dioxins in Fish Meals,
Fish Oils, Deodorizer Distillates and Filtering/Bleaching Clays - Nationwide
Survey." on June 16, 2004;
- Summarized the results to date on dioxin levels in grains, grain
by-products, fish meal, fish oil, and forages. Also summarized the dioxin
results from 14 follow-up investigations in cattle that the FDA conducted
as a result of a recent USDA survey;
- Received 28,424 adverse experience reports, over 5,000 more
than FY 2003, and reviewed 18,625 of these complaints. Because of the
severity of this year's complaints, we spent considerably more review
time than
in previous years reviewing individual adverse drug event (ADE) submissions
involving heartworm drug safety and lack of effectiveness; and,
- Finalized a curriculum for cGMP training and initiation of the
Pharmaceutical Inspectorate Training Course in August 2004. This supports
the FDA's priority of modernizing the health care system through improved
cGMPs.
Emerging Issue - Monkey-Pox
- On November 4, 2003, in collaboration with CDC, issued an interim
final rule for Monkey-Pox, a zoonotic disease that spread from imported
African rodents to prairie dogs to humans. The interim final rule is
to establish new restrictions and modify existing restrictions on the
original
FDA/CDC Joint Order adopted on June 11, 2003 under the Public Health
Service Act; and,
- Assured affected parties were notified of the Interim Final
Rule, coordinated the follow-up to possible violations of the Rule, and
evaluated requests for permits to allow movement of animals for reasons
other than those identified in the Rule. During FY 2004, FDA responded
to approximately 125 requests for a permit, mostly dealing with the capture
and transport of wild prairie dogs, to transport these animals.
Patient and Consumer Protection
Antimicrobial Resistance
- Published the final Guidance for Industry #152 document on antimicrobial
resistance on October 23, 2003. This guidance was developed with public
input and is significant because it provides a scientific, risk-based
approach to preventing antimicrobial resistance that may result from
the use of
antimicrobial drugs in food-producing animals;
- Developed a database that will be searchable from the web containing
a listing of all antimicrobials approved for use in food animals;
- Prepared a draft risk assessment to assess the link between
the use of Virginiamycin in animals and Synercid resistance in humans
and released it for public comment due back by February 23, 2005;
- Created animated video that depicts the ways bacteria typically
acquire resistance to antimicrobial drugs to advance understanding to
key audiences, particularly veterinary students and livestock producers;
- Continued to review previously approved new animal antimicrobial
drug submissions with respect to antimicrobial resistance and human food
safety;
- Completed the review of the penicillin approvals for microbiological
food safety concerns and discussed findings and recommended actions with
the drug sponsors;
- Supported an advanced WHO training course on the surveillance
of Salmonella and antimicrobial resistance in food borne pathogens; and,
- Participated in the cooperative agreement with four sites in
Mexico to determine the prevalence of Salmonella species and quinolone-resistant
E.coli from symptomatic and asymptomatic humans.
National Antimicrobial Resistance Monitoring System (NARMS)
- Continued expanding the retail meat arm of NARMS at FDA/CVM/Office
of Research by having 10 FoodNet sites collect samples from local grocery
stores and submit the isolates to the CVM/OR for antimicrobial susceptibility
testing to obtain a more representative picture of the contribution of
the food supply to antimicrobial resistance and helps sponsor with their
submissions to CVM under GFI #152;
- Continued to improve NARMS methods including development of
a Campylobacter broth microdilution method approved by the National Committee
for Clinical Laboratory Standards Veterinary Antimicrobial Susceptibility
Testing;
- Completed the first annual NARMS retail meat report on September
30, 2004, which can be found on CVM's web site. This report provides
data on the prevalence of antimicrobial resistant foodborne pathogens
and commensal
bacterial among retail meat and poultry samples;
- Enhanced the robustness of the NARMS retail meat arm by training
personnel in state public health lab sin isolation and testing methodologies.
The
retail meat arm was expanded from 6 labs in FY 2002 to 10 in FY 2004;
- Screened animal feeds and animal feed components for the presences
of resistant pathogens including Salmonella, E. coli and Enterococcus;
- Conducted numerous presentations on NARMS at national and international
scientific meetings; and,
- Completed total revision of the NARMS web page with the addition
of NARMS peer-reviewed publications and FDA Veterinarian articles.
Protecting the Homeland -- Counterterrorism
Counterterrorism
- Participated with Agencies and other sectors in coordinating:
- Food and Agriculture, Critical Infrastructure Protection Sector
-Wide Meetings;
- Foot and Mouth Disease Dairy Research Working Group;
- White House Agroterrorism Blue Ribbon Panel;
- Development and testing of emergency response plans for chemical,
biological, and radiological incidents;
- Assisted in publication and education outreach efforts for the
Bioterrorism Act of 1992 covering Registration, Prior Notice, Automatic
Detention, and Record Keeping Rules;
- Evaluated rapid laboratory methods to permit analysis of feedstuffs
for microbiological hazards, and comparing these methods to existing
cultural methods;
- Collaborated with other government agencies on the development
of a list of priority products for countermeasures which will be used
in assembling a National Strategic Veterinary Stockpile;
- Responded to Homeland Security Presidential Directives (HSPD)-7
and -9 by drafting and submitting the Animal Feeds portion of the National
Infrastructure Protection Plan which is a part of DHS National Critical
Infrastructure Protection Program, as well as, working on methods that
will integrate surveillance systems to quickly detect emerging diseases,
pests, toxic substances, and radioactive agents that threaten agriculture
and the food supply; and,
- Performed initial vulnerability assessments of animal feeds.
Improving FDA's Business Practices
Under this strategic goal, the Program supports the FDA's efforts to
strengthen its infrastructure, enhance employee performance, and take other
steps to build a high functioning organization. Some of the accomplishments
include:
- Implemented CVM's Activity Time Reporting System center-wide
with the 1st pay period of FY 2004. The system was developed
and designed to be a user friendly integrated system dedicated to supporting
the Center's Activity Based Management goals and contributing to improved
program planning/prioritization, and budget and performance integration
and management. Data from the system was utilized to support ADUFA financial
implementation and supports the tracking of allowable ADUFA costs by
activity. The Agency is developing a plan to leverage these activities
agency-wide;
- Implemented Strategic Human Capital Management - Used the Staff
College Competency Model in the recruiting and interview process to ensure
identification and selection of the best-qualified candidates for the
hiring of the new animal drug reviewers to meet the workload increase
with the
initiation of the ADUFA;
- Continued to develop and expand the CVM Staff College that was
established in
FY 2002 through a state-of-the-art Knowledge Management Center providing
the framework to support the development and delivery of a robust scientific,
management, leadership, and team building curriculum based upon researched
and established core competencies necessary for high performance in specific
positions and functional areas;
- Implemented the mandatory EEO and Diversity Management Training
Program for all managers and supervisors;
- Continued to enhance IT management consistent with the President's
expanded E-government initiative;
- Supported the implementation of the FDA IT Director's Migration
Plan that moved the Agency IT managers and staff into the Agency's Office
of the Chief Information Officer; and,
- Reduced and redistributed the administrative workload and consolidated
functions and tasks that are required in the organizational area to exceed
its 2004 targeted administrative position reductions as directed by the
Agency.
Animal Drugs and Feeds
Program Activity
Data
|
Program Workload and Outputs 1/
|
FY 2004 Actuals
|
FY 2005 Estimates
|
FY 2006 Estimates
|
New Animal Drug Applications (NADAs): [2]
|
Received
|
15
|
23
|
23
|
Completed
|
23
|
23
|
23
|
Approved
|
18
|
18
|
18
|
Pending [3]
|
3
|
3
|
3
|
New Animal Drug Application Supplements: 2 [4]
|
Received
|
408
|
408
|
408
|
Completed
|
476
|
476
|
476
|
Approved
|
356
|
356
|
356
|
Pending 3
|
156
|
88
|
20
|
Abbreviated New Animal Drug Applications (ANADAs):2
|
Received
|
61
|
61
|
61
|
Completed
|
55
|
61
|
61
|
Approved
|
19
|
19
|
19
|
Pending 3
|
47
|
47
|
47
|
Abbreviated New Animal Drug Application Supplements: 2 4
|
Received
|
211
|
241
|
241
|
Completed
|
195
|
220
|
220
|
Approved
|
163
|
183
|
183
|
Pending 3
|
78
|
99
|
120
|
Investigational New Animal Drug (INAD) Files: [5]
|
Received
|
2,138
|
2,138
|
2,138
|
Completed
|
2,200
|
2,200
|
2,200
|
Pending 3
|
264
|
202
|
140
|
Animal Drugs and Feeds
Program Activity
Data
|
Program Workload And Outputs 1/
|
FY 2004 Actuals
|
FY 2005 Estimates
|
FY 2006 Estimates
|
Generic Investigational New Animal Drug (JINAD) Files: 5
|
Received
|
170
|
170
|
170
|
Completed
|
130
|
170
|
170
|
Pending 3
|
66
|
66
|
66
|
Investigational Food Additive Petitions
|
34
|
40
|
40
|
Food (Animal) Additive Petitions [6]
|
12
|
20
|
20
|
Production & Manufacturing Defect Reports----Received
|
401*
|
2,000
|
2,000
|
----Reviewed
|
1,769
|
1,700
|
1,700
|
Adverse Experience Reports (AERs)-------------Received
|
28,424
|
27,000
|
27,000
|
-------------Reviewed
----Reviewed
|
18,625
|
18,000
|
18,000 |
Animal/Medicated Feed Partnership Agreements
|
27
|
30
|
30
|
*The FY 04 actual is lower than the FY 04 estimate because most product
defects reported in the previous period were related to the use of a single
product. The sponsor fixed the problem and the reports are lower. The FY
05 & FY 06 estimates of 2000 product defect reports a year reflect
what CVM historically receives a year.
Animal Drugs and Feeds
Program Activity Data
|
ADUFA Performance Cohort*
|
FY 2004
|
Application/Submission Type:
|
Goal:
Review & Act On
|
# Reviewed & Acted On
|
Perf.
As of 9/30/04
|
New Animal Drug Applications (NADAs)
|
NADAs & reactivations
|
90% w/in 295 days
|
5
|
100%
|
Administrative NADAs & reactivations**
|
90% w/in 90 days
|
8
|
100%
|
New Animal Drug Application Supplements & Reactivations***
|
Non-manufacturing****
(Safety & Efficacy)
|
90% w/in 320 days
|
8
|
100%
|
Manufacturing
|
90% w/in 225 days
|
230
|
100%
|
Investigational New Animal Drug (INAD) File Submissions
|
Data (Studies)
|
90% w/in 320 days
|
107
|
100%
|
Protocols
|
90% w/in 125 days
|
147
|
100%
|
This chart reflects information provided in the FY 2004 ADUFA Performance
Report.
*All FDA review performance statistics are based on fiscal year
receipt cohort. This methodology calculates performance statistics for
submissions for the fiscal year FDA received them, regardless of when FDA
ultimately acted on or approved the submissions. A consequence of this
approach is that the statistics shown for a particular year may change
from one report to the next. This is because as time passes, FDA completes
work on more and more submissions in a receipt cohort. As more submissions
are completed, the statistics for that year of receipt must be adjusted
to reflect the new completions. Until all submissions in a cohort are completed,
only a preliminary performance assessment can be provided for that cohort.
With the exception of this report, where only information for the first
reporting year (FY 2004) is available, FDA will report, in subsequent years
on two performance years for ADUFA performance. Starting with the FY 2005
report, the status of the current year and an update on the previous year
will be included.
**Administrative includes both original and supplemental applications,
including their reactivations.
***Certain supplements are excluded, such as sponsor changes,
minor changes to labeling, requests to withdraw and trade name changes,
not involving safety and/or effectiveness data.
****Non-Manufacturing hybrids are included. A "supplemental animal
drug application" is: a supplement, manufacturing or non-manufacturing,
to an application approved under section 512(c)(1) of the act (21 U.S.
C. 360b(c)(1)) (i.e., a supplement to an NADA), regardless of whether data
with respect to safety or effectiveness are required for approval; or a
supplement, manufacturing or non-manufacturing, to an application approved
under section 512(c)(2) of the act (21 U.S. C. 360b(c)(2)) (i.e., a supplement
to an ANADA), provided that data with respect to safety or effectiveness
are required for the supplement to be approved.
Performance Goal and Target
The following table of performance goal and FY 2006 target is presented
to compliment the sequential display of this program's "outputs" by more
closely linking the traditional budget presentation of base and increased
activities and workload outputs contained in the Program Activity Data
(PAD) charts. Activities discussed throughout this narrative support the
accomplishment of outputs (PAD and performance goals) which in turn contribute
to the accomplishment of long term outcome and strategic goals. Full cost
information for these goals as well as other historical information has
been provided in their respective sections in the Detail of Performance
Analysis contained in the supporting information tab.
Performance Goal
|
Target
|
Promote safe and effective animal drug availability ensuring public
and animal health by meeting ADUFA Performance goals.
This goal is dependent upon a sustained level of base and user
fee resources. (14020)
|
FY 06:
Complete review and action on 90% of original NADAs & reactivations
of such applications received in FY 2006 within 230 days.
|
![horizonal rule](https://webarchive.library.unt.edu/eot2008/20090119224551im_/http://www.fda.gov/graphics/blkpixel.gif)